2075sek
-2,6 %
Date:2026-09-08Time:17:29:42Latest report:Q2-2026List:First NorthTicker:GENO
Market Cap:1 400 msekEnterprise Value:1 316 msekNet Sales:135,6 msekEarnings:20,5 msekEmployees:0ISIN:SE0002485979

Ratios

10-year key figure history for Genovis turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Genovis with index and moving average MA50 and MA200.

Stockprice:20,75
MA50:19,96
MA200:19,62
Price/MA200:5,8 %
RSI (14):52,4
Price/MA50:3,9 %

Description

Genovis delivers biotechnology tools and technology platforms to the life sciences and pharmaceutical industries. The company develops enzyme and inhibitor technologies that facilitate, or are integral parts of, a wide range of processes from basic research to pharmaceutical manufacturing and diagnostics. The company operates on a global scale, with customers primarily in North America, Europe and East Asia. Genovis was founded in 1999 and is headquartered in Kävlinge.

Biotechnology